Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha

Authors: Isabel Conde, María VT Lobo, Javier Zamora, Julio Pérez, Francisco J González, Emilio Alba, Benito Fraile, Ricardo Paniagua, María I Arenas

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

The human pregnane X receptor (hPXR) is an orphan nuclear receptor that induces transcription of response elements present in steroid-inducible cytochrome P-450 gene promoters. This activation requires the participation of retinoid X receptors (RXRs), needed partners of hPXR to form heterodimers. We have investigated the expression of hPXR and RXRs in normal, premalignant, and malignant breast tissues, in order to determine whether their expression profile in localized infiltrative breast cancer is associated with an increased risk of recurrent disease.

Methods

Breast samples from 99 patients including benign breast diseases, in situ and infiltrative carcinomas were processed for immunohistochemistry and Western-blot analysis.

Results

Cancer cells from patients that developed recurrent disease showed a high cytoplasmic location of both hPXR isoforms. Only the infiltrative carcinomas that relapsed before 48 months showed nuclear location of hPXR isoform 2. This location was associated with the nuclear immunoexpression of RXR-alpha.

Conclusion

Breast cancer cells can express both variants 1 and 2 of hPXR. Infiltrative carcinomas that recurred showed a nuclear location of both hPXR and RXR-alpha; therefore, the overexpression and the subcellular location changes of hPXR could be considered as a potential new prognostic indicator.
Appendix
Available only for authorised users
Literature
1.
Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA: The nuclear receptor PXR is a lithocholic acids sensor that protects against liver toxicity. Proc Natl Acad Sci USA. 2001, 98: 3369-3374. 10.1073/pnas.051551698.CrossRefPubMedPubMedCentral
2.
Gardner-Stephen D, Heydel JM, Goyal A, Lu Y, Xie W, Lindblom T, Mackenzie P, Radominska-Pandya A: Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metabolism Disposition. 2004, 32: 340-347. 10.1124/dmd.32.3.340.CrossRefPubMedPubMedCentral
3.
Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, Perlmann T, Lehmann JM: An orphan nuclear receptor activated by pregnanes defines a novel steroid-signaling pathway. Cell. 1998, 92: 73-82. 10.1016/S0092-8674(00)80900-9.CrossRefPubMed
4.
Mangelsdorf DJ, Evans RM: The RXR heterodimers and orphan receptors. Cell. 1995, 83: 841-850. 10.1016/0092-8674(95)90200-7.CrossRefPubMed
5.
Lehmann JM, Mc Knee DD, Watson MA, Willson TM, Moore JT, Kliewer SA: The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 1998, 102: 1016-1023. 10.1172/JCI3703.CrossRefPubMedPubMedCentral
6.
Blumberg B, Sabbagh WJr, Juguilon H, Bolado JJr, Van Meter CM, Ong ES, Evans RM: SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 1998, 12: 3195-3205. 10.1101/gad.12.20.3195.CrossRefPubMedPubMedCentral
7.
Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, Hancock M, Kim RB, Strom S, Thummel K, Russell CG, Hudson JR, Schuetz EG, Boguski MS: The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 2001, 11: 555-572. 10.1097/00008571-200110000-00003.CrossRefPubMed
8.
Gonzalez FJ, Liu SY, Yano M: Regulation of cytochrome P450 genes: molecular mechanisms. Pharmacogenetics. 1993, 3: 51-57. 10.1097/00008571-199302000-00006.CrossRefPubMed
9.
Zhang H, LeCluyse E, Liu L, Hu M, Matoney L, Zhu W, Yan B: Rat pregnane X receptor: molecular cloning, tissue distribution and xenobiotic regulation. Arch Biochem Biophys. 1999, 368: 14-22. 10.1006/abbi.1999.1307.CrossRefPubMed
10.
Savas U, Wester MR, Griffin KJ, Johnson EF: Rabbit pregnane X receptor is activated by rifampicin. Drug Metab Dispos. 2000, 28: 529-537.PubMed
11.
LeCluyse EL: Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem-Biol Inter. 2001, 134: 283-289. 10.1016/S0009-2797(01)00163-6.CrossRef
12.
El-Rayes BF, Ali S, Heilbrun LK, Lababidi S, Bouwman D, Visscher D, Philip PA: Cytochrome P450 and glutathione transferase expression in human breast cancer. Clin Cancer Res. 2003, 9: 1705-1709.PubMed
13.
Kapucuoglu N, Coban T, Raunio H, Pelkonen O, Edwards RJ, Boobis AR, Iscan M: Expression of CYP3A4 in human breast tumor and non-tumor tissues. Cancer Lett. 2003, 202: 17-23. 10.1016/j.canlet.2003.08.015.CrossRefPubMed
14.
Dotzlaw H, Leygue E, Watson , Murphy LC: The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. Clin Cancer Res. 1999, 5: 2103-2107.PubMed
15.
Miki Y, Suzuki T, Kitada K, Yabuki N, Shibuya R, Moriya T, Ishida T, Ohuchi N, Blumberg B, Sasano H: Expression of the Steroid and Xenobiotic Receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res. 2006, 66: 535-542. 10.1158/0008-5472.CAN-05-1070.CrossRefPubMed
16.
Hellmold H, Rylander T, Magnusson M, Reihner E, Warner M, Gustafsson JA: Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasties. J Clin Endocrinol Metab. 1998, 83: 886-895. 10.1210/jc.83.3.886.PubMed
17.
Bieche I, Girault I, Urbain E, Tozlu S, Lidereau R: Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res. 2004, 6: 252-263. 10.1186/bcr784.CrossRef
18.
Huang Z, Fasco M, Figge H, Keyomarsi K, Kaminsky L: Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos. 1996, 24 (8): 899-905.PubMed
19.
Fukuen S, Fukuda T, Matsuda H, Sumida A, Yamamoto I, Inaba T, Azuma J: Identification of the novel splicing variants for the hPXR in human livers. Biochem Biophys Res Commun. 2002, 298: 433-438. 10.1016/S0006-291X(02)02469-5.CrossRefPubMed
20.
Lamba V, Yasuda K, Lamba JK, Assem M, Davila J, Strom S, Schuetz EG: PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol. 2004, 199: 251-265. 10.1016/j.taap.2003.12.027.CrossRefPubMed
21.
Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Metch B, Osborne CK: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992, 10: 1284-1291.PubMed
22.
Cai Y, Konishi T, Han G, Campwala KW, French SW, Wan Y-JY: The role of hepatocyte RXR-α in xenobiotic-sensing nuclear receptor-mediated pathways. Eur J Pharm Sci. 2002, 15: 89-96. 10.1016/S0928-0987(01)00211-1.CrossRefPubMed
23.
Masuyama H, Hiramatsu Y, Kodama J-I, Kudo T: Expression and potential roles of pregnane X receptor in endometrial cancer. J Clin Endocrinol Metab. 2003, 88: 4446-4454. 10.1210/jc.2003-030203.CrossRefPubMed
24.
Squires EJ, Sueyoshi T, Negishi M: Cytoplasmic localization of Pregnane X Receptor and ligand-dependent nuclear translocation in mouse liver. J Biol Chem. 2004, 279: 49307-49314. 10.1074/jbc.M407281200.CrossRefPubMed
25.
Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM: Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature (Lond). 1992, 355: 446-449. 10.1038/355446a0.CrossRef
26.
Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM: Convergene of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimers formation of their receptors. Nature (Lond). 1992, 358: 771-774. 10.1038/358771a0.CrossRef
27.
Lawrence JA, Merino MJ, Simpson JF, Manrow RE, Page DL, Steeg PS: A high-risk lesion for invasive breast cancer, ductal carcinoma in situ, exhibits frequent overexpression of retinoid X receptor. Cancer Epidemiol Biomarkers Prev. 1998, 7: 29-35.PubMed
28.
Ariga N, Moriya T, Suzuki T, Kimura M, Ohuchi N, Sasano H: Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. Jpn J Cancer Res. 2000, 91: 1169-1176.CrossRefPubMed
29.
Suzuki T, Moriya T, Sugawara A, Ariga N, Takabayashi H, Sasano H: Retinoid receptors in human breast carcinoma: possible modulators of in situ estrogen metabolism. Breast Cancer Res Treat. 2001, 65: 31-40. 10.1023/A:1006433929792.CrossRefPubMed
30.
Pratt WB, Toft DO: Steroid receptor interactions with heat shock proteins and immunophilin chaperones. Endocr Rev. 1997, 18: 306-360. 10.1210/er.18.3.306.PubMed
31.
Zhan S-K, Lehmann J, Hoffmann B, Dawson MI, Cameron J, Graupner G, Hhermann T, Tran P, and Pfahl M: Homodimer formation of retinoid X receptor induced by 9-cis- retinoic acid. Nature (Lond). 1992, 358: 587-591. 10.1038/358587a0.CrossRef
32.
Crowe DL, Chandraratna AS: A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res. 2004, 6: R546-R555. 10.1186/bcr913.CrossRefPubMedPubMedCentral
33.
Baum M, Houghton J, Riley D: Tamoxifen to prevent breast cancer. Lancet. 1991, 338: 114-10.1016/0140-6736(91)90104-W.CrossRefPubMed
34.
Dorssers LC, Flier Van der S, Brinkman A, van Agthoven T, Veldscholte J, Bems EM, Klijn JG, Beex LV, Foekens JA: Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs. 2001, 61: 1721-1733. 10.2165/00003495-200161120-00004.CrossRefPubMed
35.
Clemons M, Danson S, Howell A: Tamoxifen ('Nolvadex'): a review. Cancer Treat Rev. 2002, 28: 165-180. 10.1016/S0305-7372(02)00036-1.CrossRefPubMed
36.
Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM: Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002, 30: 869-874. 10.1124/dmd.30.8.869.CrossRefPubMed
37.
Desai PB, Nallani SC, Sane RS, Moore LB, Goodwin BJ, Buckley DJ, Buckley AR: Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos. 2002, 30: 608-612. 10.1124/dmd.30.5.608.CrossRefPubMed
38.
Iscan M, Klaavuniemi T, Coban T, Kapucuoglu N, Pelkonen O, Raunio H: The expression of cytochrome P450 enzymes in human breast tumors and normal breast tissue. Breast Cancer Res Treat. 2001, 70: 47-54. 10.1023/A:1012526406741.CrossRefPubMed
39.
Modugno F, Knoll C, Kanbour-Shakir A, Romkes M: A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003, 82: 191-197. 10.1023/B:BREA.0000004376.21491.44.CrossRefPubMed
40.
Sane RS, Buckley DJ, Buckley AR, Nallani SC, Desai PB: Role of human Pregnane X Receptor in tamoxifen and 4-hydroxytamoxifen mediated CYP3A4 induction in primary human hepatocytes and LS174T cells. Drug Metab Dispos. 2008 February 25
41.
Synold TW, Dussault I, Forman BM: The orphan nuclear receptor SXR co-ordinately regulates drug metabolism and efflux. Nature Med. 2001, 7: 584-590. 10.1038/87912.CrossRefPubMed
Metadata
Title
Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha
Authors
Isabel Conde
María VT Lobo
Javier Zamora
Julio Pérez
Francisco J González
Emilio Alba
Benito Fraile
Ricardo Paniagua
María I Arenas
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-174

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy

Research article

Overexpression of CDC2/CyclinB1 in gliomas, and CDC2 depletion inhibits proliferation of human glioma cells in vitro and in vivo

Research article

Comparative study of the radiosensitising and cell cycle effects of vinflunine and vinorelbine, in vitro

Research article

Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivoanalysis

Research article

Leptin receptor Gln223Arg polymorphism and breast cancer risk in Nigerian women: A case control study

Research article

Self evaluation of communication experiences after laryngeal cancer – A longitudinal questionnaire study in patients with laryngeal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits